Anthropic CEO: AI will help defeat most diseases in 5–10 years

Artificial intelligence could, in the future, give humanity the ability to cure or prevent most diseases within just 5–10 years. This opinion was expressed by Dario Amodei, co-founder and CEO of Anthropic (the developer of Claude).

Amodei published his prediction on the social network X on August 16. He acknowledged that such a forecast might seem overly optimistic even to experts in the field of biology but considers it quite realistic—provided that the development of powerful AI systems continues at the current pace. "I actually think it will be possible to cure most human diseases in about 5–10 years," wrote the head of Anthropic.

An important caveat: this is not about the emergence of some single universal medicine or a confirmed medical prognosis. Rather, it is a scenario of how much artificial intelligence is capable of accelerating biological research and the development of new therapeutic methods.

Ideas from the essay Machines of Loving Grace

Amodei elaborated on this concept earlier in an essay titled Machines of Loving Grace. According to his calculations, a sufficiently powerful AI could potentially accelerate the development of biology and medicine by approximately tenfold—thereby shortening a path that under normal conditions might take 50–100 years down to 5–10 years.

Among the possible results of such acceleration, the head of Anthropic named a sharp reduction in the incidence and mortality from cancer, the prevention or treatment of most genetic diseases, progress in the fight against Alzheimer's disease, more effective therapy for cardiovascular and autoimmune diseases, and new approaches to treating diabetes and obesity.

At the same time, Amodei acknowledged that the actual pace of progress would still be constrained by the need to conduct laboratory research, clinical trials, and obtain regulatory approvals—stages that artificial intelligence cannot bypass.

Anthropic expands projects in biology and medicine

In his new publication, Amodei also stated that Anthropic is rapidly ramping up work in the fields of biology and medicine. According to him, the company expects to see the first signs of noticeable results in the coming months, and more significant achievements in the following years. However, the head of Anthropic emphasized that the artificial intelligence industry as a whole has not yet fulfilled many of its most ambitious promises.

Previously, Anthropic launched the AI for Science program, which gives researchers access to the company's models for projects in biology, genetics, and the search for new drugs.

The AI Opinion

From the perspective of machine data analysis, Amodei's statement should be viewed not only as a scientific forecast but also as part of a broader corporate context. According to The Insider, Anthropic's valuation following the latest funding round exceeded $960 billion, and the company's projected annual revenue has grown to $47 billion compared to $10 billion for the entire year 2025. With such investments, investors have the right to expect not only new versions of Claude but also tangible practical results, and breakthroughs in biology and medicine are one of the few arguments capable of justifying such a valuation in the eyes of the market.

The macroeconomic connection here is obvious: the faster a company's capitalization grows, the stronger the demands on it to show concrete achievements beyond chatbots and code generation. The technical aspect remains open—will the acceleration of research turn into real treatment methods, or will the result be limited to improved data analysis models that only speed up certain stages of scientists' work?